DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

DEXCOM INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$85.98−0.06 (-0.07%)

Close on Oct 19, 2026

Market cap: $33.54B
P/E (TTM): 34.1
Dividend yield: –

Fundamental chart

Pick a measure to chart its full history

$4.66BFY2025, +34.1% a year since FY2011

Where these numbers come from

Parsed from the XBRL in Dexcom's annual and quarterly filings with the SEC
Per-share figures adjusted for the 4-for-1 split on Jun 13, 2022
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is DXCM.

Revenue growth15.5% · median 14.3%

Gross margin62.5% · median 54.9%

Operating margin22.9% · median 2.0%

Net margin20.1% · median -6.1%

Company	Revenue	Growth
DXCM	$4.97B	+15.5%
MMED	$3.10B	+14.3%
PODD	$3.05B	+29.4%
TFX	$2.25B	+30.7%
ICUI	$2.16B	-9.0%
TNDM	$1.04B	+4.0%

Company

Next earnings (est.): Oct 29, 2026, after close
Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 11,100
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 1093557

Advertisement
300 × 250